Enliven Therapeutics, Inc.
General ticker "ELVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.0B (TTM average)
Enliven Therapeutics, Inc. follows the US Stock Market performance with the rate: 36.2%.
Estimated limits based on current volatility of 3.2%: low 27.83$, high 29.70$
Factors to consider:
- Total employees count: 46 as of 2023
- Current price 12.7% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.35$, 24.30$]
- 2026-12-31 to 2027-12-31 estimated range: [8.82$, 21.14$]
Short-term ELVN quotes
Long-term ELVN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $83.53MM | $104.55MM | $119.66MM |
| Operating Income | $-83.53MM | $-104.55MM | $-119.66MM |
| Non-Operating Income | $11.95MM | $15.76MM | $15.96MM |
| R&D Expense | $64.57MM | $80.78MM | $85.86MM |
| Income(Loss) | $-71.58MM | $-88.79MM | $-103.69MM |
| Taxes | $0.00MM | $0.23MM | $0.00MM |
| Profit(Loss)* | $-71.58MM | $-89.02MM | $-103.69MM |
| Stockholders Equity | $245.91MM | $309.85MM | $459.60MM |
| Assets | $271.87MM | $325.76MM | $476.17MM |
| Operating Cash Flow | $-61.27MM | $-73.19MM | $-70.30MM |
| Capital expenditure | $0.15MM | $0.04MM | $0.16MM |
| Investing Cash Flow | $-148.41MM | $-36.00MM | $-173.84MM |
| Financing Cash Flow | $234.29MM | $133.16MM | $218.87MM |
| Earnings Per Share** | $-2.01 | $-1.89 | $-1.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.